Chapter 21. First- and second-generation H1 antihistamines: From the molecular basis of their interaction with HERG K+ channels to physiological and pathophysiological implication

Clinical and Experimental Allergy Reviews

Volumn 4, Issue SUPPL. 2, 2004, Pages 183-190

  Taglialatela, Maurizio ^a   Castaldo, P ^a   Pannaccione, A ^a   Secondo, A ^a   Cataldi, M ^a   Boscia, F ^a   Annunziato, L ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antihistamines; Long QT syndrome; Potassium channels

Indexed keywords

ACRIVASTINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; DIPHENHYDRAMINE; DOFETILIDE; EBASTINE; EMEDASTINE; FEXOFENADINE; HYDROXYZINE; IBUPROFEN; ITRACONAZOLE; KETOCONAZOLE; KETOTIFEN; LEVOCABASTINE; LORATADINE; MACROLIDE; MIZOLASTINE; NORASTEMIZOLE; ORPHENADRINE; OXATOMIDE; PHENIRAMINE; POTASSIUM CHANNEL HERG; PROMETHAZINE; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPROLIDINE; UNINDEXED DRUG;

ADENOHYPOPHYSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHROMAFFIN CELL; CONFERENCE PAPER; CONVULSION; EPILEPTIC STATE; GRAND MAL SEIZURE; HEART ARREST; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE POTENTIAL; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN CELL; LEARNING DISORDER; NONHUMAN; PANCREAS CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QT PROLONGATION; REGULATORY MECHANISM; SEDATION; SIDE EFFECT; SINUS TACHYCARDIA; SYNCOPE; TORSADE DES POINTES;

EID: 11844277639     PISSN: 14729725     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-9725.2004.00053.x     Document Type: Conference Paper

References (57)

1. Dale HH, Laidlaw PP. The physiological action of B-iminazoyethylamine. J Physiol 1910; 41:341-44.
2. Staub AM, Bovet D. Action de la thymoxyethyldiethylamine (929F) et des ethers phenolique sur le choc anaphylactique. Comp rend Soc Biol 1937; 125:818-821.
3. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36:233-52.
4. Yanai K, Okamura N, Tagawa M et al. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy 1999; 29(Suppl. 3):29-36.
5. 1-Receptor Antagonists in Allergic Diseases. New York: Marcel Dekker, 1996:383-412.
6. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. Br Med J 2000; 320:1158-9.
7. Schwartz PJ, Locati EH, Napolitano C, Priori SG. The long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology. From Cell to Bedside (2nd ed.). Philadelphia: WB Saunders, 1995:788-811.
8. Warmke J, Drysdale R, Ganetzky B. A distinct potassium channel polypeptide encoded by the Drosophila eag locus. Science 1991; 252:1560-2.
9. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81:299-307.
10. Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94:817-23.
11. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385:77-80.
12. Taglialatela M, Pannaccione A, Castaldo P et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998; 54:113-21.
13. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet 1997; 349:1322.
14. Taglialatela M, Pannaccione A, Castaldo P et al. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine. Br J Pharmacol 2000; 131:1081-8.
15. Khalifa M, Drolet B, Daleau P et al. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther 1999; 288:858-65.
16. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21:52-6.
17. Pratt CM, Hertz RP, Ellis BE et al. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994; 73:346-52.
18. Emmi A, Wenzel HJ, Schwartzkroin PA et al. Do glia have heart? Expression and functional role for ether-a-go-go currents in hippocampal astrocytes. J Neurosci 2000; 18:3915-25.
19. Saganich MJ, Machado E, Rudy BJ. Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci 2001; 21:4609-24.
20. + channel encoding genes ERG1, ERG2 and ERG3 in the adult rat central nervous system. J Comp Neurol 2003; 466:119-35.
21. 3 cells. J Biol Chem 1999; 274:7508-15.
22. Berridge MJ. The AM and FM of calcium signalling. Nature 1997; 386:759-60.
23. Dolmetsch RE, Xu K, Lewis R. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 1998; 392:933-6.
24. Corette BJ, Bauer CK, Schwarz JR. An inactivating inward-rectifying K current present in prolactin cells from the pituitary of lactating rats. J Membr Biol 1996; 150:185-95.
25. Bauer CK. The inwardly rectifying K+ current and its modulation by thyrotrophin-releasing hormone in giant clonal rat anterior pituitary cells. J Physiol 1998; 510:63-70.
26. Bauer CK, Schafer R, Sciemann D et al. A functional role of erg-like inward-rectifying K+ current in prolactin secretion from rat lactotrophs. Mol Cell Endocrinol 1999; 148:37-45.
27. 3 cells. Mol Pharmacol 2000; 58:1115-28.
28. 2+ channels (SOCs). Biochem Pharmacol 2001; 62:1229-38.
29. Lecchi M, Redaelli E, Rosati B et al. Isolation of a long-lasting eag-related gene-type K+ current in MMQ lactotrophs and its accommodating role during slow firing and prolactin release. J Neurosci 2002; 22:3414-25.
30. Gullo F, Ales E, Rosati B et al. ERG K+ channel blockade enhances firing and epinephrine secretion in rat chromaffin cells: the missing link to LQT2-related sudden death? FASEB J 2003; 17:330-2.
31. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 1989; 54:87-143.
32. Rosati B, Marchetti P, Crociani O et al. Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: the role of HERG K(+) channels in firing and release. FASEB J 2000; 14:2601-10.
33. Taglialatela M. Heterologous expression systems and drug screening procedures for ion channel drug discovery. In: Pugsley MK, ed. Cardiac Drug Development Guide. Totowa, NJ: Humana Press, 2003; 227-44.
34. Hollister LE. Hydroxyzine hydrochloride: possible adverse cardiac interactions. Psychopharmacol Comm 1975; 1:61-5.
35. Magera BE, Betlach CJ, Sweatt AP, Derrick CW Jr. Hydroxyzine intoxication in a 13-month-old child. Pediatrics 1981; 67:280-3.
36. Hestand HE, Teske DW. Diphenhydramine hydrochloride intoxication. J Pediatr 1977; 90:1017-8.
37. Krenzelok EP, Anderson GM, Mirick M. Massive diphenhydramine overdose resulting in death. Ann Emerg Med 1982; 11:212-3.
38. Rinder CS, D'Amato SL, Rinder HM, Cox PM. Survival in complicated diphenhydramine overdose. Crit Care Med 1988; 16:1161-2.
39. Clark RF, Vance MV. Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate. Ann Emerg Med 1992; 21:318-21.
40. Zareba W, Moss AJ, Rosero SZ, Hajj-Ali R, Konecki J, Andrews M. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997; 80:1168-73.
41. Olson KR, Kearney TE, Dyer JE, Benowitz NL, Blanc PD. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1993; 11:565-8.
42. Danze LK, Langdorf MI. Reversal of orphenadrine-induced ventricular tachycardia with physostigmine. J Emerg Med 1991; 9:453-7.
43. Malizia E, Sarcinelli L, Pascarella M, Ambrosini M, Smeriglio M, Russo A. Cardiotoxicity from orphenadrine intoxication in humans. Arch Toxicol Suppl 1980; 4:425-7.
44. Sangster B, van Heijst AN, Zimmerman AN. Treatment of orphenadrine overdose. N Engl J Med 1977; 296:1006.
45. Sangster B, Van Heijst AN, Zimmerman AN, De Vries HW. Intoxication by orphenadrine HCL; mechanism and therapy. Acta Pharmacol Toxicol (copenh) 1977; 41:129-36.
46. Bozza-Marrubini M, Frigerio A, Ghezzi R, Parelli L, Restelli L, Selenati A. Two cases of severe orphenadrine poisoning with atypical features. Acta Pharmacol Toxicol (copenh) 1977; 41:137-52.
47. Kondou N, Hiasa Y, Kishi K et al. A case of life-threatening ventricular arrhythmias probably due to psychotropic drugs. Kokyu to Junkan 1993; 41:1117-20.
48. Bobik A, McLean AJ. Cardiovascular complications due to pheniramine overdosage. Aust NZ J Med 1976; 6:65-7.
49. Chouinard G, Ghadirian AM, Jones BD. Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule. Can Med Assoc J 1978; 119:729-30.
50. Leor J, Harman M, Rabinowitz B, Mozes B. Giant U waves and associated ventricular tachycardia complicating astemizole overdose: successful therapy with intravenous magnesium. Am J Med 1991; 91:94-7.
51. Hoppu K, Tikanoja T, Tapanainen P, Remes M, Saarenpaa-Heikkila O, Kouvalainen K. Accidental astemizole overdose in young children. Lancet 1991; 338:538-40.
52. Craft TM. Torsade de pointes after astemizole overdose. Br Med J 1986; 292:660.
53. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996; 28:1556-61.
54. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264:2788-90.
55. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989; 298:325.
56. Pinto YM, van Gelder IC, Heeringa M, Crijns HJ. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999; 353:980-1.
57. Dhar S, Hazra PK, Malakar S, Mistri G. Fexofenadine-induced QT prolongation: a myth or fact? Br J Dermatol 2000; 142:1260-1.